INVO Bioscience (INVO) Competitors

Spectral AI (NASDAQ:MDAI) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.

Do insiders and institutionals have more ownership in MDAI or INVO?

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are held by institutional investors. 56.7% of Spectral AI shares are held by company insiders. Comparatively, 3.5% of INVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more volatility & risk, MDAI or INVO?

Spectral AI has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Is MDAI or INVO more profitable?

Spectral AI has a net margin of -40.78% compared to INVO Bioscience's net margin of -122.79%.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-40.78%	N/A	-77.87%
INVO Bioscience	-122.79%	N/A	-36.94%

Does the MarketBeat Community prefer MDAI or INVO?

Spectral AI and INVO Bioscience both received 7 outperform votes by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote.

Company	Underperform	Outperform
Spectral AI	Outperform Votes 7 100.00%	Underperform Votes No Votes
INVO Bioscience	Outperform Votes 7 46.67%	Underperform Votes 8 53.33%

Which has preferable earnings & valuation, MDAI or INVO?

INVO Bioscience has lower revenue, but higher earnings than Spectral AI.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$29.58M	1.10	-$20.85M	-$0.84	-1.54
INVO Bioscience	$5.77M	1.06	-$8.03M	N/A	N/A

Do analysts rate MDAI or INVO?

Spectral AI currently has a consensus price target of $4.75, suggesting a potential upside of 268.22%. Given Spectral AI's stronger consensus rating and higher probable upside, analysts plainly believe Spectral AI is more favorable than INVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
INVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media prefer MDAI or INVO?

In the previous week, Spectral AI had 4 more articles in the media than INVO Bioscience. MarketBeat recorded 5 mentions for Spectral AI and 1 mentions for INVO Bioscience. Spectral AI's average media sentiment score of 0.92 beat INVO Bioscience's score of 0.00 indicating that Spectral AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spectral AI beats INVO Bioscience on 12 of the 15 factors compared between the two stocks.